Localised breast cancer: neoadjuvant chemotherapy impact evaluation on the pathological complete response (PCR) in a lower middle-income country

被引:0
|
作者
Adjade, Ganiou [1 ]
Tafenzi, Hassan Abdelilah [1 ,2 ]
Jouihri, Houda [1 ]
Al Tamimi, Nadin Shawar [1 ]
Bennouna, Yousra [1 ]
Negamiyimana, Gustave [1 ]
Cisse, Kalil [1 ]
Essadi, Ismail [2 ,3 ]
El Fadli, Mohammed [1 ]
Belbaraka, Rhizlane [1 ,2 ]
机构
[1] Mohammed VI Univ Hosp, Dept Med Oncol, 2360 Marrakech Principal, Marrakech, Morocco
[2] Cady Ayyad Univ, Fac Med & Pharm, Biosci & Lab, 7010 Sidi Abbad, Marrakech 40000, Morocco
[3] Avicenna Mil Hosp, Dept Med Oncol, Marrakech 40000, Morocco
来源
ECANCERMEDICALSCIENCE | 2023年 / 17卷
关键词
chemotherapy; neoadjuvant; breast cancer; localised; PCR; Morocco; SURGERY; THERAPY;
D O I
10.3332/ecancer.2023.1648
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Neoadjuvant chemotherapy followed by surgery remains the current rec-ommended therapeutic strategy for the management of locally advanced breast cancer. The standard chemotherapy protocol is sequential with anthracycline followed by tax-anes. However public hospitals in Morocco are confronted with a shortage in healthcare products. We, therefore, evaluated the efficacy of the different protocols proposed to patients, by evaluating the clinical response after chemotherapy especially through the pathological complete response (PCR) after surgery. Methods: We focused on the database of the medical oncology department of the only public hospital covering middle and southern Morocco. We included patients diagnosed between 2018 and 2020. Two groups of patients distinguished in group A (GA) received the standard therapy, and group B (GB) received a non-standard protocol. The therapeu-tic response was assessed clinically before surgery and then by pathological examination of the surgical specimens. The Sataloff classification defined the histological response for both tumour and lymph nodes. We included both groups in one variable to determine their impact on outcomes. A logistic regression-based analysis was adopted to define variables related to the PCR.Results: Over the study period, 120 patients met our inclusion criteria. They were distin-guished at 72% in GA and 28% in GB. 60.8% over 120 got a partial response, whereas, only 33.3% achieved a complete response. The general PCR rate was 28% with 14.3% in GB and 85.7% in GA. The tumour PCR was obtained in 40 (33.3%) over 120 patients and 51.7% of lymph node PCR. The multivariate logistic regression analysis results show no relative factors associated with general PCR achievement.Conclusion: These first interesting results from an institutional database inform us about our clinical practice and require additional research using prospective randomised con-trolled studies.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Pathological complete response (pCR) after neoadjuvant chemotherapy in luminal breast cancer
    Cordoba Ortega, J. F.
    Gasol Cudos, A.
    Morales Murillo, S.
    Vilardell Villellas, F.
    Siso Raber, C.
    Canosa Morales, C.
    Salud Salvia, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S313 - S313
  • [2] Time to surgery after neoadjuvant chemotherapy in breast cancer and its impact on survival in a middle-income country.
    Garcia, Katherine
    Sandoya, Lorena
    Morquecho, Walter
    Paulson, Guillermo
    Santacruz, Mayra
    Castro, Norma
    Engracia, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Complete pathological response to neoadjuvant chemotherapy and its impact on breast cancer outcomes
    Boudaouara, O.
    Ben Makhlouf, W.
    Bouhamed, M.
    Graja, S.
    Charfi, S.
    Boudawara, T. Sellami
    Ben Kridis, W.
    VIRCHOWS ARCHIV, 2024, 485 : S189 - S189
  • [4] Occult breast cancer with pathological complete response to neoadjuvant chemotherapy
    Ren, Ningning
    Liu, Shuo
    Shi, Peng
    Tian, Xingsong
    ASIAN JOURNAL OF SURGERY, 2024, 47 (11) : 4949 - 4951
  • [5] Pathological complete response (ypCR) in early and locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy in a middle-income country. Results from a real-world historical cohort
    Mantilla, William
    Gonzalez, Maria-Fernanda
    Rojas, Sebastian
    Borras-Osorio, Mariana
    Molano-Gonzalez, Nicolas
    Guerra, Joaquin
    Munevar, Isabel
    Moran, Diego
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Biomarkers Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
    Li, Xiaoxian
    Krishnamurti, Uma
    Bhattarai, Shristi
    Klimov, Sergey
    Reid, Michelle
    Aneja, Ritu
    LABORATORY INVESTIGATION, 2016, 96 : 54A - 54A
  • [7] Biomarkers Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
    Li, Xiaoxian
    Krishnamurti, Uma
    Bhattarai, Shristi
    Klimov, Sergey
    Reid, Michelle
    Aneja, Ritu
    MODERN PATHOLOGY, 2016, 29 : 54A - 54A
  • [8] Pathological Complete Response Patients after Neoadjuvant Chemotherapy in Breast Cancer
    Takaoka, Megumi
    Ohsumi, Shozo
    Ikejiri, Haruka
    Shidahara, Tomohiro
    Miyoshi, Yuichiro
    Takahashi, Mina
    Takashima, Seiki
    Aogi, Kenjiro
    ACTA MEDICA OKAYAMA, 2022, 76 (02) : 105 - 111
  • [9] Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy
    Montemurro, Filippo
    Di Cosimo, Serena
    BREAST, 2014, 23 (05): : 690 - 691
  • [10] Impact of pathological complete response to neoadjuvant chemotherapy in invasive breast cancer according to molecular subtype
    Cirier, J.
    Body, G.
    Jourdan, M. -L.
    Bedouet, L.
    Fleurier, C.
    Pilloy, J.
    Arbion, F.
    Ouldamer, L.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2017, 45 (10): : 535 - 544